

AMERICAN VANGUARD CORP  
Form 8-K  
December 24, 2003

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (date of earliest event reported): December 23, 2003**

---

**AMERICAN VANGUARD CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**0-6354**  
Commission File Number

**95-2588080**  
(I.R.S. Employer Identification No.)

**4695 MacArthur Court**  
**Newport Beach, California 92660**  
(Address of principal executive offices)

Registrant's telephone number: (949) 260-1200

---

**Item 5. Other Events.**

On December 23, 2003, American Vanguard announced that AMVAC Chemical Corporation, a wholly owned subsidiary of the Company, completed the acquisition of certain assets related to the active ingredient dichlorvos ( DDVP ) used in the animal health business and marketed primarily under the trade name Nuvan from Novartis Animal Health, Inc., a business unit of Novartis AG. All more particularly described in Exhibit 99.1.

**Item 7. Exhibits.**

99.1 Press release issued December 23, 2003

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AMERICAN VANGUARD CORPORATION**

(Registrant)

By:                   /s/ James A. Barry                  

James A. Barry

Senior Vice President

Chief Financial Officer

Date: December 23, 2003

**INDEX TO EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated December 23, 2003, of American Vanguard Corporation.